Evidence map›Paper›PMID 30353682›Full record

ArticleJournal of diabetes investigation2019

Serum 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid is associated with lipid profiles and might protect against non-alcoholic fatty liver disease in Chinese individuals.

Jiarong Dai, Jufen Yi, Shan Zhang, Peihong Chen, Hua Jin, Xuemei Yu, Xueli Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jiarong DaiThe Third School of Clinical Medicine, Southern Medical University, Guangzhou, China.ORCID http://orcid.org/0000-0002-2804-4019
Jufen YiDepartment of Endocrinology and Metabolism, Diabetes Ward, Fengxian Central Hospital Affiliated to the Southern Medical University, Shanghai, China.
Shan ZhangDepartment of Endocrinology and Metabolism, Diabetes Ward, Fengxian Central Hospital Affiliated to the Southern Medical University, Shanghai, China.
Peihong ChenDepartment of Endocrinology and Metabolism, Diabetes Ward, Fengxian Central Hospital Affiliated to the Southern Medical University, Shanghai, China.
Hua JinDepartment of Endocrinology and Metabolism, Diabetes Ward, Fengxian Central Hospital Affiliated to the Southern Medical University, Shanghai, China.
Xuemei YuThe Third School of Clinical Medicine, Southern Medical University, Guangzhou, China.ORCID http://orcid.org/0000-0002-0621-9375
Xueli ZhangDepartment of Endocrinology and Metabolism, Diabetes Ward, Fengxian Central Hospital Affiliated to the Southern Medical University, Shanghai, China.
Xian Central Hospital · CN

Funding

Shanghai Municipal Commission of Health and Family Planning, China 201640272, ZK2015A02
6 · The paper itself

Abstract

AIMS/

introductionHigh plasma 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) levels are significantly associated with type 2 diabetes mellitus, which is usually accompanied by metabolic syndrome and non-alcoholic fatty liver disease (NAFLD) with increased triglyceride levels. Thus, we hypothesized that elevated CMPF levels might be related to lipid metabolism and NAFLD risk. MATERIALS AND

methodsSerum CMPF levels were determined using an enzyme-linked immunosorbent assay in a total of 466 individuals, including 116 controls with no NAFLD or type 2 diabetes mellitus, 53 individuals with NAFLD but no type 2 diabetes mellitus, 151 individuals with type 2 diabetes mellitus but no NAFLD, and 146 individuals with both NAFLD and type 2 diabetes mellitus. The associations with age, blood pressure, lipid profiles, body mass index and liver injury marker levels were examined, and a meta-analysis of non-diabetic and diabetic groups was carried out to detect the combined effects.

resultsThe CMPF concentration in NAFLD patients was significantly lower than individuals without NAFLD in both the non-diabetic group (P < 0.05) and diabetic group (P < 0.01), and correlated negatively with several parameters of liver function and the adiposity index. Meta-analysis showed that serum CMPF levels was associated with decreased risk of NAFLD after combining the results (odds ratio 0.677, 95% confidence interval 0.552-0.831, P < 0.001). Additionally, the CMPF concentration was independently negatively associated with triglycerides and high-density lipoprotein cholesterol in the meta-analysis. Multiple stepwise regression analysis showed that body mass index, high-density lipoprotein cholesterol, triglyceride level, age, sex and fasting plasma glucose were independently associated with CMPF (all P < 0.05).

conclusionsThe results suggest that serum CMPF levels are negatively related to lipid metabolism and could be used to predict NAFLD development.

Indexed as

Asian PeopleBiomarkersCase-Control StudiesDiabetes Mellitus, Type 2FemaleFollow-Up StudiesFuransHumansLipidsMaleMiddle AgedNon-alcoholic Fatty Liver DiseasePrognosisPropionates3-carboxy-4-methyl-5-propyl-2-furanpropanoic acidBiomarkersFuransLipidsPropionates3-Carboxy-4-methyl-5-propyl-2-furanpropanoic acidNon-alcoholic fatty liver diseaseTriglycerides

Identifiers

PMID30353682
PMCPMC6497611
OpenAlexW2898515258

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.